Biotechnology | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved Eli Lilly and Company’s osteoporosis drug, Evista, to reduce the risk of invasive breast cancer
On Sept. 14, 2007, the U.S. Food and Drug Administration (FDA) announced it had approved Eli Lilly’s osteoporosis…